Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.

Molecular cancer therapeutics - 1 Jun 2015

Schwaederle Maria, Daniels Gregory A, Piccioni David E, Fanta Paul T, Schwab Richard B, Shimabukuro Kelly A, Parker Barbara A, Kurzrock Razelle

Abstract excerpt

Despite the increased use of molecular diagnostics, the extent to which patients who have these tests harbor potentially actionable aberrations is unclear. We retrospectively reviewed 439 patients with diverse cancers, for whom next-generation sequencing (mostly 236-gene panel) had been performed. Data pertaining to the molecular alterations identified, as well as associated treatment suggestions (on- or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Genetic Predisposition to Disease

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasms

Share to Precision Medicine

Source

Identifiers

PMID: 25852059
DOI: 10.1158/1535-7163.MCT-14-1061

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.PMID 25852059Read ↗

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.Semantic proximity Read ↗

A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.Semantic proximity Read ↗

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersSemantic proximity Read ↗

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.Semantic proximity Read ↗

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.Semantic proximity Read ↗

Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.Semantic proximity Read ↗

Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health systemSemantic proximity Read ↗

Clinical Use of Precision Oncology Decision SupportSemantic proximity Read ↗

Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers.Semantic proximity Read ↗

Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.Semantic proximity Read ↗

Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.Semantic proximity Read ↗

Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing PanelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.